Suzanne J.A. Korporaal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Suzanne J.A. Korporaal has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Jan-Willem N. Akkerman
2 shared publicationsBerny M
1 shared publicationC. Arnold Koekman
From the Department of Clinical Chemistry and Haematology (S.J.A.K., C.A.K., S.V., D.E.v.d.W., M.B., J.-W.N.A.), University Medical Center, Utrecht, and the Division of Biopharmaceutics (S.J.A.K., M.V.E.), Leiden/Amsterdam Center for Drug Research, Gorlaeus Laboratories, Leiden University, the Netherlands
1 shared publicationDianne E. van der Wal
From the Department of Clinical Chemistry and Haematology (S.J.A.K., C.A.K., S.V., D.E.v.d.W., M.B., J.-W.N.A.), University Medical Center, Utrecht, and the Division of Biopharmaceutics (S.J.A.K., M.V.E.), Leiden/Amsterdam Center for Drug Research, Gorlaeus Laboratories, Leiden University, the Netherlands
1 shared publicationGailani D
1 shared publicationGertz J
1 shared publication
Latest Publications
- 1 March 2009
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 29 (3) , 372-379
Downregulation of Platelet Responsiveness Upon Contact With LDL by the Protein-Tyrosine Phosphatases SHP-1 and SHP-2
Objective—The sensitivity of platelets to aggregating agents increases when low-density lipoprotein (LDL) binds to apolipoprotein E receptor 2′ (apoER2′), triggering activation of p38MAPKand formation of thromboxane A2. LDL signaling is terminated by PECAM-1 through recruitment and activation of the Ser/Thr protein phosphatase PP2A, but platelets remain unresponsive to LDL when PECAM-1 activation disappears. We report a second mechanism that halts LDL signaling and in addition lowers platelet responsiveness to aggregating agents.Methods and Results—After a first stimulation with LDL, platelets remain unresponsive to LDL for 60 minutes, despite normal apoER2′ activation by a second dose of LDL. A possible cause is persistent activation of the tyrosine phosphatases SHP-1 and SHP-2, which may not only block a second activation of p38MAPK, PECAM-1, and PP2A by LDL but also seem to reduce aggregation by TRAP, collagen, and ADP.Conclusion—These findings reveal that p38MAPKphosphorylation and platelet activation by LDL are suppressed by two mechanisms: (1) short activation of PECAM-1/PP2A, and (2) prolonged activation of SHP-1 and SHP-2. Activation of SHP-1 and SHP-2 is accompanied by reduced responsiveness to aggregating agents, which—if present in vivo—would make LDL an aggregation inhibitor during prolonged contact with platelets.
- 1 March 2009
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 29 (3) , 372-379
Downregulation of Platelet Responsiveness Upon Contact With LDL by the Protein-Tyrosine Phosphatases SHP-1 and SHP-2
Objective—The sensitivity of platelets to aggregating agents increases when low-density lipoprotein (LDL) binds to apolipoprotein E receptor 2′ (apoER2′), triggering activation of p38MAPKand formation of thromboxane A2. LDL signaling is terminated by PECAM-1 through recruitment and activation of the Ser/Thr protein phosphatase PP2A, but platelets remain unresponsive to LDL when PECAM-1 activation disappears. We report a second mechanism that halts LDL signaling and in addition lowers platelet responsiveness to aggregating agents.Methods and Results—After a first stimulation with LDL, platelets remain unresponsive to LDL for 60 minutes, despite normal apoER2′ activation by a second dose of LDL. A possible cause is persistent activation of the tyrosine phosphatases SHP-1 and SHP-2, which may not only block a second activation of p38MAPK, PECAM-1, and PP2A by LDL but also seem to reduce aggregation by TRAP, collagen, and ADP.Conclusion—These findings reveal that p38MAPKphosphorylation and platelet activation by LDL are suppressed by two mechanisms: (1) short activation of PECAM-1/PP2A, and (2) prolonged activation of SHP-1 and SHP-2. Activation of SHP-1 and SHP-2 is accompanied by reduced responsiveness to aggregating agents, which—if present in vivo—would make LDL an aggregation inhibitor during prolonged contact with platelets.
- 1 July 2006
- Published by S. Karger AG in Pathophysiology of Haemostasis and Thrombosis
- Vol. 35 (3-4) , 270-280
Platelet Activation by Low Density Lipoprotein and High Density Lipoprotein
Cardiovascular disease is the main cause of death and disability in the Western society. Lipoproteins are important in the development of cardiovascular disease since they change the properties of different cells involved in atherosclerosis and thrombosis. The interaction of platelets with lipoproteins has been under intense investigation. Particularly the initiation of platelet signaling pathways by low density lipoprotein (LDL) has been studied thoroughly, since platelets of hypercholesterolemic patients, whose plasma contains elevated LDL levels due to absent or defective LDL receptors, show hyperaggregability in vitro and enhanced activity in vivo. These observations suggest that LDL enhances platelet responsiveness. Several signaling pathways induced by LDL have been revealed in vitro, such as signaling via p38 mitogen-activated protein kinase and p125 focal adhesion kinase. High density lipoprotein (HDL) consists of two subtypes, HDL2 and HDL3, which have opposing effects on platelet activation. This review provides a summary of the activation of signaling pathways after platelet-LDL and platelet-HDL interaction, with special emphasis on their role in the development of thrombosis and atherosclerosis.
- 1 July 2006
- Published by S. Karger AG in Pathophysiology of Haemostasis and Thrombosis
- Vol. 35 (3-4) , 270-280
Platelet Activation by Low Density Lipoprotein and High Density Lipoprotein
Cardiovascular disease is the main cause of death and disability in the Western society. Lipoproteins are important in the development of cardiovascular disease since they change the properties of different cells involved in atherosclerosis and thrombosis. The interaction of platelets with lipoproteins has been under intense investigation. Particularly the initiation of platelet signaling pathways by low density lipoprotein (LDL) has been studied thoroughly, since platelets of hypercholesterolemic patients, whose plasma contains elevated LDL levels due to absent or defective LDL receptors, show hyperaggregability in vitro and enhanced activity in vivo. These observations suggest that LDL enhances platelet responsiveness. Several signaling pathways induced by LDL have been revealed in vitro, such as signaling via p38 mitogen-activated protein kinase and p125 focal adhesion kinase. High density lipoprotein (HDL) consists of two subtypes, HDL2 and HDL3, which have opposing effects on platelet activation. This review provides a summary of the activation of signaling pathways after platelet-LDL and platelet-HDL interaction, with special emphasis on their role in the development of thrombosis and atherosclerosis.
- 1 July 2006
- Published by S. Karger AG in Pathophysiology of Haemostasis and Thrombosis
- Vol. 35 (3-4) , 305-313
Lipoprotein-Associated Proteins Involved in Platelet Signaling
Platelets and lipoproteins are both key elements in the development of atherosclerosis and thrombosis. Based on their density, five classes of lipoproteins have been identified which all influence platelets via distinct mechanisms. The activation of platelets starts with binding of apolipoproteins to different platelet receptors and is followed by the activation of signaling pathways resulting in activation or inhibition of platelet functions like aggregation or secretion. In addition to apolipoproteins, lipoproteins are also associated to a large amount of proteins, enzymes and lipids that also can induce platelet activation or inhibition. This review provides a summary of the activation of signaling pathways after platelet–lipoprotein interactions initiated by lipoprotein-associated proteins and lipids.
- 1 July 2006
- Published by S. Karger AG in Pathophysiology of Haemostasis and Thrombosis
- Vol. 35 (3-4) , 305-313
Lipoprotein-Associated Proteins Involved in Platelet Signaling
Platelets and lipoproteins are both key elements in the development of atherosclerosis and thrombosis. Based on their density, five classes of lipoproteins have been identified which all influence platelets via distinct mechanisms. The activation of platelets starts with binding of apolipoproteins to different platelet receptors and is followed by the activation of signaling pathways resulting in activation or inhibition of platelet functions like aggregation or secretion. In addition to apolipoproteins, lipoproteins are also associated to a large amount of proteins, enzymes and lipids that also can induce platelet activation or inhibition. This review provides a summary of the activation of signaling pathways after platelet–lipoprotein interactions initiated by lipoprotein-associated proteins and lipids.